1113 related articles for article (PubMed ID: 19858391)
21. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
22. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
Overmoyer B; Silverman P; Holder LW; Tripathy D; Henderson IC
Clin Breast Cancer; 2005 Jun; 6(2):150-7. PubMed ID: 16001993
[TBL] [Abstract][Full Text] [Related]
25. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
26. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
Martin M; Lluch A; Ojeda B; Barnabas A; Colomer R; Massuti B; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-26-S17-30. PubMed ID: 9374088
[TBL] [Abstract][Full Text] [Related]
28. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Biganzoli L; Cufer T; Bruning P; Coleman RE; Duchateau L; Rapoport B; Nooij M; Delhaye F; Miles D; Sulkes A; Hamilton A; Piccart M
Cancer; 2003 Jan; 97(1):40-5. PubMed ID: 12491503
[TBL] [Abstract][Full Text] [Related]
30. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
Weber B; Lortholary A; Mayer F; Bourgeois H; Orfeuvre H; Combe M; Platini C; Cretin J; Fric D; Paraiso D; Pujade-Lauraine E
Anticancer Res; 2009 Oct; 29(10):4195-200. PubMed ID: 19846972
[TBL] [Abstract][Full Text] [Related]
31. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
32. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
33. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
[TBL] [Abstract][Full Text] [Related]
34. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
[TBL] [Abstract][Full Text] [Related]
36. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
37. A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients.
Wildiers H; Jurcut R; Ganame J; Herbots L; Neven P; De Backer J; Denys H; Cocquyt V; Rademakers F; Voigt JU; Paridaens R
Crit Rev Oncol Hematol; 2008 Aug; 67(2):133-8. PubMed ID: 18308582
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
[TBL] [Abstract][Full Text] [Related]
39. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
40. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Gil-Gil MJ; Bellet M; Morales S; Ojeda B; Manso L; Mesia C; Garcia-Martínez E; Martinez-Jáñez N; Melé M; Llombart A; Pernas S; Villagrasa P; Blasco C; Baselga J
Breast Cancer Res Treat; 2015 Jun; 151(3):597-606. PubMed ID: 25981896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
